[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide]

Gynecol Obstet Fertil. 2010 Nov;38(11):660-2. doi: 10.1016/j.gyobfe.2010.09.002. Epub 2010 Oct 27.
[Article in French]

Abstract

Objectives: To evaluate the effect of Temozolomide on female fertility and the relevance of our coverage in preservation of fertility.

Patients and methods: From 2005 to 2009, 24 patients treated with Temozolomide for a low-grade glioma were included in the study (12 women who underwent a fertility preservation consultation and 12 women who did not). A retrospective study of their medical records and sending a questionnaire were undertaken to assess their fertility after treatment.

Results: Of the 24 patients, 15 patients had no fertility preservation and the remaining nine had a cryopreservation of embryos with or without an oocyte cryopreservation. Four patients are or have been pregnant (delivery, spontaneous miscarriage, pregnancy being in the group of preserving fertility and a current pregnancy in the group where no fertility preservation has been achieved).

Discussion: First study on the effect of Temozolomide on female fertility.

Conclusion: Temozolomide is not totally gonadotoxic.

MeSH terms

  • Adult
  • Antineoplastic Agents, Alkylating / adverse effects*
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Cryopreservation
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Embryo, Mammalian
  • Female
  • Glioma / drug therapy*
  • Humans
  • Infertility, Female / chemically induced*
  • Infertility, Female / prevention & control
  • Oocytes
  • Pregnancy
  • Pregnancy Outcome
  • Reproductive Techniques, Assisted
  • Retrospective Studies
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide